Monneret Guillaume, Venet Fabienne, Pachot Alexandre, Lepape Alain
Hospices civils de Lyon, Immunology laboratory, Hopital E. Herriot, Lyon, France.
Mol Med. 2008 Jan-Feb;14(1-2):64-78. doi: 10.2119/2007-00102.Monneret.
Septic syndromes represent a major although largely underrecognized healthcare problem worldwide, accounting for thousands of deaths every year. It is now agreed that sepsis deeply perturbs immune homeostasis by inducing an initial tremendous systemic inflammatory response which is accompanied by an antiinflammatory process, acting as negative feedback. This compensatory inhibitory response secondly becomes deleterious as nearly all immune functions are compromised. These alterations might be directly responsible for worsening outcome, as they may play a major role in the decreased resistance to nosocomial infections in patients who survived initial resuscitation. Consequently, immunostimulatory therapies may now be assessed for the treatment of sepsis. This review focuses on immune dysfunctions described in septic patients and on their potential use as markers on a routine standardized basis for prediction of adverse outcome or of occurrence of secondary nosocomial infections. This constitutes a prerequisite to a staging system for individualized treatment for these hitherto deadly syndromes.
脓毒症综合征是一个重大的医疗问题,尽管在全球范围内很大程度上未得到充分认识,每年导致数千人死亡。目前人们一致认为,脓毒症通过引发最初的巨大全身炎症反应并伴有抗炎过程(作为负反馈),从而严重扰乱免疫稳态。这种代偿性抑制反应其次会变得有害,因为几乎所有免疫功能都会受到损害。这些改变可能直接导致预后恶化,因为它们可能在初始复苏后存活的患者对医院感染抵抗力下降中起主要作用。因此,现在可以评估免疫刺激疗法用于脓毒症的治疗。本综述重点关注脓毒症患者中描述的免疫功能障碍,以及它们作为常规标准化标志物用于预测不良预后或继发性医院感染发生的潜在用途。这是为这些迄今为止致命的综合征制定个体化治疗分期系统的先决条件。